Deal activity by value related to cloud increased by 186% year-on-year in 2022 in the pharmaceutical industry  

Analysis of the key themes driving deal activity reveals that cloud accounted for 104 pharmaceutical deals between 2018 and 2022, worth a total value of $7,817m, according to GlobalData’s Deals database covering mergers and acquisitions, private equity, venture financing, equity offerings and partnerships.  

The $40m venture financing issue by Curebase was the largest disclosed deal in 2022, while the $15m venture financing by Seven Bridges Genomics was the largest disclosed deal in 2021.  

In value terms, cloud-related deal activity increased by 186% year-on-year in 2022, whereas it declined by 97% year-on-year in 2021.  

Venture financing accounted for the highest number of deals in the last five years, with 44 deals, followed by partnerships (26 deals) and equity offerings (16 deals).

The top financial advisor supporting deals related to cloud in the pharmaceutical industry in the last five years in terms of value was Morgan Stanley, followed by Goldman Sachs and China Renaissance Holdings.

The top legal advisors supporting deals related to cloud in the pharmaceutical industry in the last five years in terms of value were Clifford Chance, Norton Rose Fulbright, and Skadden, Arps, Slate, Meagher & Flom & Affiliates with a deal value of $5,800m each.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.  

GlobalData’s Deals database provides comprehensive coverage across industries tracking market activity of global mergers & acquisitions, including asset acquisitions/divestments; private equity deals (PE); venture finance deals (VC); equity offerings, including IPOs, follow-on offerings, and private placements; debt offerings, including private placements, ESG bonds and loans; partnerships; and licensing agreements.  

 This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumored deals.